Related Experiment Video
Updated: Apr 25, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
Ticagrelor: a novel drug for an old problem.
Andrea Rognoni, Chiara Cavallino, Alessandro Lupi
1Coronary Care Unit and Catheterization Laboratory, "Maggiore della Carità" Hospital, Corso Mazzini 18, 28100 Novara, Italy. arognoni@hotmail.com.
Recent Patents on Cardiovascular Drug Discovery
|September 2, 2014
Summary
This paper reviews ticagrelor, a new antiplatelet drug crucial for managing acute coronary syndromes. It summarizes ticagrelor
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes are a leading cause of death in industrialized nations.
- Platelet aggregation is central to the development of acute coronary syndromes and atherothrombotic disease.
- Antiplatelet therapy is vital for managing conditions involving platelet activation and thrombosis.
Purpose of the Study:
- To summarize the pharmacological properties of ticagrelor.
- To outline the clinical characteristics and therapeutic applications of ticagrelor.
Main Methods:
- Review of pharmacological data on ticagrelor.
- Analysis of clinical trial data and therapeutic guidelines for ticagrelor use.
Main Results:
- Ticagrelor is a novel oral antiplatelet agent with a significant role in treating acute coronary syndromes.
- Its pharmacological profile and clinical efficacy support its routine use in cardiovascular disease management.
Conclusions:
- Ticagrelor represents an important advancement in antiplatelet therapy for acute coronary syndromes.
- Understanding its properties is essential for optimizing patient outcomes in cardiovascular medicine.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
01:28Depolarizing Blockers: Mechanism of Action
3.3K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.3K
01:21G-Protein Gated Ion Channels
5.4K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.4K